Maha Alkofide
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maha Alkofide has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Abdulaziz Madani
Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
2 shared publications- Hend M. Alotaibi
Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
2 shared publications - Naif Ahmed Alshehri
Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
2 shared publications Sarah Alsukait
Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
2 shared publicationsBandar Ahmed Alharbi
Department of Dermatology, Riyadh First Health Cluster, King Saud Medical City, Riyadh, Saudi Arabia
1 shared publicationBasel Almalki
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-12
Risankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes
Background: Risankizumab (anti–IL-23 p19) is an established therapy for moderate-to-severe psoriasis, with strong trial efficacy and growing real-world evidence. However, long-duration outcomes and treatment-spacing patterns from the Gulf region remain limited. Objective: To evaluate long-term effectiveness, safety, and treatment patterns—including extended-interval dosing—of Risankizumab in a real-world tertiary center. Methods: Single-center retrospective cohort of adults treated with Risankizumab between January 2020 and January 2025. Primary outcome: Psoriasis Area and Severity Index (PASI) 100 on last visit. Secondary outcomes: changes in Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Dermatology Life Quality Index (DLQI) and Nail Psoriasis Severity Index (NAPSI); adverse events; treatment persistence and dosing intervals. Non-parametric tests were used; predictors of PASI 100 were explored with multivariable logistic regression. Results: We included 144 patients (mean age 39.3± 14.9 years; 55.6% male; mean BMI 29.0± 6.5). At last visit, 61.1% achieved PASI 100. Mean scores improved from baseline to last visit: PASI 7.24→ 0.34, BSA 9.81%→ 0.26%, DLQI 7.64→ 0.68, NAPSI 9.56→ 2.94 (all p< 0.001). Adverse events were infrequent (3.5%), all mild; no major adverse cardiovascular events or deaths occurred. A single case of lung cancer was reported and considered unlikely to be treatment related. A quarter of patients transitioned to extended intervals (most commonly every 4– 6 months), with the majority maintaining disease control and relapse occurring infrequently and only after ≥ 6 months. Longer treatment duration and maintenance of standard dosing frequency were associated with achieving PASI 100, while positive family history was associated with lower odds of complete clearance. Conclusion: In routine practice, Risankizumab achieved high complete-clearance rates with excellent tolerability over ~31 months’ mean exposure. Extended-interval dosing was feasible in selected stable responders. These findings align with trial durability and regional registry signals and support individualized long-term strategies.
- 1 October 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-12
Open AccessRisankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes
Background: Risankizumab (anti–IL-23 p19) is an established therapy for moderate-to-severe psoriasis, with strong trial efficacy and growing real-world evidence. However, long-duration outcomes and treatment-spacing patterns from the Gulf region remain limited. Objective: To evaluate long-term effectiveness, safety, and treatment patterns—including extended-interval dosing—of Risankizumab in a real-world tertiary center. Methods: Single-center retrospective cohort of adults treated with Risankizumab between January 2020 and January 2025. Primary outcome: Psoriasis Area and Severity Index (PASI) 100 on last visit. Secondary outcomes: changes in Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Dermatology Life Quality Index (DLQI) and Nail Psoriasis Severity Index (NAPSI); adverse events; treatment persistence and dosing intervals. Non-parametric tests were used; predictors of PASI 100 were explored with multivariable logistic regression. Results: We included 144 patients (mean age 39.3± 14.9 years; 55.6% male; mean BMI 29.0± 6.5). At last visit, 61.1% achieved PASI 100. Mean scores improved from baseline to last visit: PASI 7.24→ 0.34, BSA 9.81%→ 0.26%, DLQI 7.64→ 0.68, NAPSI 9.56→ 2.94 (all p< 0.001). Adverse events were infrequent (3.5%), all mild; no major adverse cardiovascular events or deaths occurred. A single case of lung cancer was reported and considered unlikely to be treatment related. A quarter of patients transitioned to extended intervals (most commonly every 4– 6 months), with the majority maintaining disease control and relapse occurring infrequently and only after ≥ 6 months. Longer treatment duration and maintenance of standard dosing frequency were associated with achieving PASI 100, while positive family history was associated with lower odds of complete clearance. Conclusion: In routine practice, Risankizumab achieved high complete-clearance rates with excellent tolerability over ~31 months’ mean exposure. Extended-interval dosing was feasible in selected stable responders. These findings align with trial durability and regional registry signals and support individualized long-term strategies.
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-8
Impact of Bariatric Surgery on Quality of Life and Psychological Well-Being Among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with obesity, substantial psychosocial burden, and symptom-related discomfort. Bariatric surgery achieves sustained weight loss and may improve psychological well-being, yet its effect on HS-related quality of life and symptom burden remains uncertain. To evaluate the association of bariatric surgery with psychological well-being, quality of life, and pain among patients with HS using validated patient-reported outcome measures. We conducted a analytical cross-sectional study between January 2024 and January 2025 at King Saud University Medical City, Riyadh, Saudi Arabia. Consecutive adult patients with HS were enrolled after informed consent. Disease severity was assessed using Hurley staging. Participants completed the Dermatology Life Quality Index (DLQI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and a visual analog scale (VAS) for pain. Outcomes were compared between patients with and without prior bariatric surgery using independent t-tests and general linear models adjusted for age, sex, Hurley stage, and diagnostic delay. Among 135 participants, 77 (57.0%) were female and 15 (11.1%) had undergone bariatric surgery. Patients with prior bariatric surgery had lower mean DLQI (8.13 vs 8.62), PHQ-9 (5.73 vs 7.50), GAD-7 (5.87 vs 6.31), and VAS pain (2.80 vs 3.69) scores than those without surgery; however, these differences were not statistically significant after adjustment (all p>0.05). DLQI correlated positively with PHQ-9 (r=0.334) and GAD-7 (r=0.323), while pain correlated moderately with DLQI (r=0.546; p<0.001). In this cross-sectional sample, prior bariatric surgery was not associated with statistically significant differences in quality of life, depressive symptoms, anxiety symptoms, or pain after adjustment. However, patients with prior bariatric surgery showed consistently lower mean scores across these outcomes. Larger prospective longitudinal studies with more detailed surgical subgroup data are needed to determine the magnitude and durability of any potential benefit.
- 1 May 2026
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 19, 1-8
Open AccessImpact of Bariatric Surgery on Quality of Life and Psychological Well-Being Among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with obesity, substantial psychosocial burden, and symptom-related discomfort. Bariatric surgery achieves sustained weight loss and may improve psychological well-being, yet its effect on HS-related quality of life and symptom burden remains uncertain. To evaluate the association of bariatric surgery with psychological well-being, quality of life, and pain among patients with HS using validated patient-reported outcome measures. We conducted a analytical cross-sectional study between January 2024 and January 2025 at King Saud University Medical City, Riyadh, Saudi Arabia. Consecutive adult patients with HS were enrolled after informed consent. Disease severity was assessed using Hurley staging. Participants completed the Dermatology Life Quality Index (DLQI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7), and a visual analog scale (VAS) for pain. Outcomes were compared between patients with and without prior bariatric surgery using independent t-tests and general linear models adjusted for age, sex, Hurley stage, and diagnostic delay. Among 135 participants, 77 (57.0%) were female and 15 (11.1%) had undergone bariatric surgery. Patients with prior bariatric surgery had lower mean DLQI (8.13 vs 8.62), PHQ-9 (5.73 vs 7.50), GAD-7 (5.87 vs 6.31), and VAS pain (2.80 vs 3.69) scores than those without surgery; however, these differences were not statistically significant after adjustment (all p>0.05). DLQI correlated positively with PHQ-9 (r=0.334) and GAD-7 (r=0.323), while pain correlated moderately with DLQI (r=0.546; p<0.001). In this cross-sectional sample, prior bariatric surgery was not associated with statistically significant differences in quality of life, depressive symptoms, anxiety symptoms, or pain after adjustment. However, patients with prior bariatric surgery showed consistently lower mean scores across these outcomes. Larger prospective longitudinal studies with more detailed surgical subgroup data are needed to determine the magnitude and durability of any potential benefit.